(RTTNews) -  Eli Lilly & Co. (LLY: News ) said that Effient, an oral antiplatelet agent, exhibited greater antiplatelet activity than high dose clopidogrel in Type 2 diabetes mellitus patients with coronary artery disease or CAD.

The OPTIMUS-3 or Third Optimizing anti-Platelet Therapy In Diabetes MellitUS study, which evaluated 35 patients with type 2 diabetes who also had CAD and were taking aspirin, showed that within four hours, the level of platelet inhibition as measured using the VerifyNow P2Y12 Test with a 60 mg loading dose of Effient was higher than observed with a 600 mg loading dose of clopidogrel.

The study also looked at the maintenance doses of Effient and clopidogrel. After seven days, results showed that a 10 mg maintenance dose of Effient achieved greater platelet inhibition than a 150 mg maintenance dose of clopidogrel.
Daiichi Sankyo Co. Ltd., and Eli Lilly co-developed Effient, an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries Ltd.

Click here to receive FREE breaking news email alerts for Eli Lilly And Co. and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com